AstraZeneca PLC

AZN

GB0009895292

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Employees

89,900

Sector

Pharmaceuticals

Calendar

2024-09-24 - Bernstein Pharma Conference

More about the company

Income Statement and Estimates

More financial data

Analysis / Opinion

ASTRAZENECA : Set to conquer new highs backed by ambitious goals

September 11, 2024 at 04:54 am EDT

Pascal Soriot, CEO of AstraZeneca : New lung cancer treatment shows two-month improvement in survival

September 10, 2024 at 07:48 am EDT

More Strategies

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

157.92USD

Average target price

183.64USD

Spread / Average Target

+16.29%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - London S.E. Other stock markets 11:35:09 2024-09-19 am EDT			5-day change	1st Jan Change
11,898.00 ^GBX	+0.35%		-1.26%	+12.25%

Sep. 18	European Equities Close Lower in Wednesday Trading; EU, Euro Area Inflation Declines in August	MT
Sep. 18	AstraZeneca Says US FDA Approves Fasenra for Rare Vasculitis Treatment	MT

European Equities Close Lower in Wednesday Trading; EU, Euro Area Inflation Declines in August	Sep. 18	MT
AstraZeneca Says US FDA Approves Fasenra for Rare Vasculitis Treatment	Sep. 18	MT
Glum trade for FTSE 100 before Fed decides	Sep. 18	AN
ASTRAZENECA : Goldman Sachs maintains a Buy rating	Sep. 18	ZD
AstraZeneca: new US approval for Fasenra	Sep. 18	CF
AstraZeneca Fasenra treatment for EGPA approved in the US	Sep. 18	AN
Legal & General sells CALA arm for GBP1.35 billion	Sep. 18	AN
US FDA Approves AstraZeneca's Fasenra to Treat Rare, Immune-mediated Vasculitis EGPA	Sep. 18	MT
AstraZeneca PLC's Fasenra Approves in the US for Eosinophilic Granulomatosis with Polyangiitis	Sep. 18	CI
REGENXBIO Inc. Announces Chief Financial Officer Changes	Sep. 17	CI
REGENXBIO Inc. Announces Executive Changes	Sep. 17	CI
ASTRAZENECA : JP Morgan keeps its Buy rating	Sep. 17	ZD
Sanofi, AstraZeneca Win US Approval for New RSV Vaccine Manufacturing Line	Sep. 16	MT
European Equities Close Mostly Lower in Monday Trading; Deutsche Bank Aims to Block UniCredit From Buying Commerzbank Stake	Sep. 16	MT
Sanofi Shipping Beyfortus in US Ahead of Respiratory Syncytial Virus Disease Season	Sep. 16	MT
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell as Investors Mull Possible Rate Cut	Sep. 16	MT
AstraZeneca Says Hepatocellular Carcinoma Combination Therapy Trial Showed 'Sustained, Clinically Meaningful Overall Survival Benefit' at 5 Years	Sep. 16	MT
AstraZeneca: several positive results in cancer	Sep. 16	CF
AstraZeneca celebrates survival rate of Imfinzi-Imjudo mix	Sep. 16	AN
AstraZeneca's Trial Shows IMFINZI Reduces Risk of Recurrence, Death in Patients With Bladder Cancer	Sep. 16	MT
AstraZeneca's Imfinzi Combination Shows Sustained Survival Rate at Five-year Follow-up	Sep. 16	MT
ASTRAZENECA : UBS reiterates its Sell rating	Sep. 16	ZD
AstraZeneca Reports Positive Results from Trial of Imfinzi in Muscle-invasive Bladder Cancer	Sep. 16	MT
AstraZeneca Announces Positive Results from the Niagara Phase III Trial	Sep. 15	CI
SOPHiA GENETICS Presents Multimodal Research on AI-Driven Patient Stratification at ESMO 2024	Sep. 14	CI

AstraZeneca PLC

Equities

AZN